Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition.

Sanofi missed estimates for both earnings and sales in the fourth quarter. Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher ...

L'Oréal is selling nearly 30 million shares in Sanofi, decreasing its stake in the drugmaker from 9.4% to 7.2%.

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

PARIS — L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros.

L’Oréal remains an important shareholder of Sanofi and is fully supportive of the company’s value creation strategy,” said ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Regeneron (NASDAQ: REGN )'s flagship eye drug franchise, consisting of EYLEA HD and EYLEA, saw U.S. net sales increase 2% to ...